Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial

[1]  D. McCance,et al.  Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. , 2007, Atherosclerosis.

[2]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[3]  T. Wong,et al.  Management of diabetic retinopathy: a systematic review. , 2007, JAMA.

[4]  Jie Zhang,et al.  Association of statin use with the risk of developing diabetic retinopathy. , 2007, Archives of ophthalmology.

[5]  Lois E. H. Smith,et al.  Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis , 2007, Nature Medicine.

[6]  W. Ambrosius,et al.  Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). , 2007, The American journal of cardiology.

[7]  Jeong-Hun Kim,et al.  Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. , 2007, Experimental eye research.

[8]  Z. Yildirim,et al.  The Importance of Serum Lipids in Exudative Diabetic Macular Edema in Type 2 Diabetic Patients , 2007, Annals of the New York Academy of Sciences.

[9]  Helen K. Li,et al.  Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. , 2007, Archives of ophthalmology.

[10]  A. Neubauer,et al.  Laser Treatment in Diabetic Retinopathy , 2007, Ophthalmologica.

[11]  S. Sizmaz,et al.  Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy , 2006, Eye.

[12]  I. Rodriguez,et al.  Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. , 2006, Molecular vision.

[13]  L. Aiello,et al.  Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. , 2006, Ophthalmology.

[14]  K. Erkiliç,et al.  Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy , 2006, British Journal of Ophthalmology.

[15]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[16]  E. Agrón,et al.  Serum inflammatory markers in diabetic retinopathy. , 2005, Investigative ophthalmology & visual science.

[17]  J. J. Wang,et al.  Dyslipidaemia and microvascular disease in the retina , 2005, Eye.

[18]  M. Bartoli,et al.  Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. , 2005, Current drug targets.

[19]  F. Boucher,et al.  Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. , 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[20]  J. Manson,et al.  A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. , 2004, Diabetes.

[21]  Massimo Porta,et al.  Current approaches and perspectives in the medical treatment of diabetic retinopathy. , 2004, Pharmacology & therapeutics.

[22]  R. Češka,et al.  Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. , 2004, European journal of pharmacology.

[23]  J. Shaw,et al.  The metabolic syndrome: prevalence in worldwide populations. , 2004, Endocrinology and metabolism clinics of North America.

[24]  Vishali Gupta,et al.  Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. , 2004, American journal of ophthalmology.

[25]  D. Lackland,et al.  Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. , 2004, Investigative ophthalmology & visual science.

[26]  L. M. Aiello,et al.  Perspectives on diabetic retinopathy. , 2003, American journal of ophthalmology.

[27]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[28]  I. Makino,et al.  Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. , 2003, International immunopharmacology.

[29]  T. Chowdhury,et al.  The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? , 2002, Eye.

[30]  L. Bouter,et al.  Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. , 2002, Diabetes care.

[31]  E. Fleck,et al.  PPAR activators inhibit endothelial cell migration by targeting Akt. , 2002, Biochemical and biophysical research communications.

[32]  J. Hradec,et al.  Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT). , 2001, Cardiovascular research.

[33]  N. Ferrara.  Role of vascular endothelial growth factor in regulation of physiological angiogenesis. , 2001, American journal of physiology. Cell physiology.

[34]  Stephen J. Aldington,et al.  UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.

[35]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[36]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[37]  F. Ferris,et al.  Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. , 1998, Investigative ophthalmology & visual science.

[38]  M. Losada,et al.  Malondialdehyde serum concentration in type 1 diabetic with and without retinopaty , 1997, Documenta Ophthalmologica.

[39]  B. Hoogwerf,et al.  Serum Lipids and Diabetic Retinopathy , 1996, Diabetes Care.

[40]  B. Hoogwerf,et al.  Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. , 1996, Archives of ophthalmology.

[41]  Stephen J. Aldington,et al.  Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study , 1995, Diabetologia.

[42]  H. Freyberger,et al.  [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent]. , 1994, Medizinische Klinik.

[43]  L. Yannuzzi,et al.  The effects of lipid lowering on diabetic retinopathy. , 1991, American journal of ophthalmology.

[44]  F. Ferris,et al.  Photocoagulation for diabetic macular edema. , 1987, Archives of ophthalmology.

[45]  T. Dornan,et al.  Low density lipoprotein cholesterol: An association with the severity of diabetic retinopathy , 1982, Diabetologia.

[46]  B. Harrold,et al.  A Double-blind Controlled Trial of Clofibrate in the Treatment of Diabetic Retinopathy , 1969, Diabetes.

[47]  B. Clarke,et al.  A Three-Year Trial of Atromid Therapy in Exudative Diabetic Retinopathy , 1968, Diabetes.

[48]  Anushka Patel Fracp.  Eff ects of a fi xed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007 .

[49]  Grupa badawcza Pkc-Drs.  The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy. Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical Trial , 2005 .

[50]  E. Rencová,et al.  [Objective evaluation of the success of treatment in exudative diabetic maculopathy]. , 1992, Ceskoslovenska oftalmologie.

[51]  P. Dodson,et al.  Long term follow-up of and underlying medical conditions in patients with diabetic exudative maculopathy , 1991, Eye.

[52]  Dorne Pa.  [Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced but prolonged dosage over several years (author's transl)]. , 1977 .

[53]  J. F. Cullen,et al.  A controlled trial of Atromid therapy in exudative diabetic retinopathy. , 1964, Transactions of the ophthalmological societies of the United Kingdom.